Industry

Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS®(celecoxib 56-mg and tramadol hydrochloride 44mg)CI-V as an Efficacious Alternative for Moderate-to-Severe Acute Pain in Appropriate Patients

Phase 3 clinical trial data in patients post-bunionectomy demonstrated SEGLENTIS as an efficacious and well-tolerated multimodal treatment option for appropriate adult patients with acute pain. MONTGOMERY, Ala.–(BUSINESS WIRE)–Kowa Pharmaceuticals America, Inc. announced the publication of Phase 3 clinical trial results in Pain Practice reinforcing that SEGLENTIS® a unique co-crystal combination of celecoxib 56-mg and tramadol … [Read more…]

Rite Aid and Quest Diagnostics Expand Access to COVID-19 PCR Testing Nationwide

Testing available at no out-of-pocket cost for qualified insured individuals at Rite Aid drive-thru locations with appointment; at all other Rite Aid locations customers can schedule to pick up at-home specimen collection kits for PCR testing PHILADELPHIA & SECAUCUS, N.J.–(BUSINESS WIRE)–Rite Aid (NYSE: RAD) today announced it is collaborating with Quest Diagnostics (NYSE: DGX) to … [Read more…]

New Study of Aerin Medical’s RhinAer® Shows Positive Clinical and Quality-of-Life Results Following Treatment for Chronic Rhinitis

Largest study of RhinAer to date shows 87% of patients reported quality-of-life improvements SUNNYVALE, Calif.–(BUSINESS WIRE)–#ENT—Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced the publication of positive results from the RELIEF clinical trial in the American Journal of Rhinology & … [Read more…]

Pharma Proposes to Work with G7 and G20 on a Joint Solution for Better Access to Vaccines and Treatments Around the World for Future Pandemics

For future pandemics, we will build on the achievements which led to developing and scaling up multiple safe and effective vaccines and innovative treatments against COVID-19 in historic record time, collaborating with partners all over the world and executing on access plans. The innovative biopharmaceutical industry applauds the G7’s commitment to strengthening global pandemic preparedness … [Read more…]

LifeWorks declares July 2022 cash dividend

TORONTO–(BUSINESS WIRE)–(TSX: LWRK) LifeWorks Inc. (the “Company” or “LifeWorks”) announced today a cash dividend of $0.065 per share for the month of July 2022, to be paid on August 15, 2022 to holders of record of shares of LWRK on July 29, 2022. LifeWorks designates this dividend to be an “eligible dividend” pursuant to subsection … [Read more…]

Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Enhance Opioid Analgesia and Inhibit Opioid-derived Dependence, Withdrawal and Respiratory Depression

ROCKVILLE, Md.–(BUSINESS WIRE)–Creative Bio-Peptides, Inc, a preclinical-stage biotechnology company developing novel therapies to balance the innate immune system and promote regeneration of damaged neurons, today announced the publication of findings from a preclinical study showing that treatment with the multi-chemokine receptor antagonist oral peptide RAP-103 substantially reduced heroin self-administration and motivation to consume heroin. RAP-103 … [Read more…]

Agiliti Announces Second Quarter 2022 Earnings Release Date and Conference Call

MINNEAPOLIS–(BUSINESS WIRE)–Agiliti Inc. (NYSE: AGTI) (“Agiliti”) today announced that the company will release its second quarter results after the market close on Tuesday, August 9, 2022, to be followed by a conference call at 5 p.m. Eastern Time on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0792 … [Read more…]

Koneksa Appoints Dr. Maria C. Freire to Board of Directors

NEW YORK–(BUSINESS WIRE)–#BoardofDirectors—Koneksa, a healthcare technology company pioneering digital biomarkers, today announced the appointment of Maria C. Freire, Ph.D., to its Board of Directors. Dr. Freire is an accomplished executive and public health leader with a proven track record in enabling life sciences companies to maximize the potential of their technology platforms. “Koneksa is privileged … [Read more…]

Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx

˗ PMA supplement will further expand oncoReveal™ Dx indication/label to include ability to detect additional eight cancer types ˗ Company continues to execute on its strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing NATICK, Mass.–(BUSINESS WIRE)–Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) … [Read more…]

Tectonic Therapeutic Strengthens Leadership Team

BOSTON–(BUSINESS WIRE)–Tectonic Therapeutic, Inc. a pre-clinical stage biotechnology company transforming the discovery of novel GPCR-targeted therapies (G-Protein Coupled Receptors), today announced the promotion of Senior Vice President, Head of Research, Peter McNamara, PhD, to Chief Scientific Officer as well as the appointments of Barry Rubenstein as Senior Vice President, People and Culture and Washington Alves … [Read more…]